A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and methylcholanthrene-induced primary tumours, to demonstrate that a novel water-soluble combretastatin A-4 derivative, AC7700, abruptly and irreversibly stopped tumour blood flow. As a result of this interrupted supply of nutrients, extensive necrosis was induced within the tumour. In the present study, we investigated whether AC7700 acts in the same way against solid tumours growing in the liver, stomach, kidney, muscle, and lymph nodes. Tumour blood flow and the change in tumour blood flow induced by AC7700 were measured by the hydrogen clearance method. In a model of cancer chemotherapy against metastases, LY80 cells (2x10(6)) were injected into the lateral tail vein, and AC7700 at 10 mg x kg(-1) was injected i.v. five times at intervals of 2 days, starting on day 7 after tumour cell injection. The number and size of tumours were compared with those in the control group. The change in tumour blood flow and the therapeutic effect of AC7700 on microtumours were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber. AC7700 caused a marked decrease in the tumour blood flow of all LY80 tumours developing in various tissues and organs and growth of all tumours including lymph node metastases and microtumours was inhibited. In every tumour, tumour blood flow began to decrease immediately after AC7700 administration and reached a minimum at approximately 30 min after injection. In many tumour capillaries, blood flow completely stopped within 3 min after AC7700 administration. These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases. We conclude that tumour blood flow stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers because the therapeutic effect is independent of tumour site and specific type of cancer.
Hori
K
K
Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. k-hori@idac.tohoku.ac.jp
Saito
S
S
Kubota
K
K
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use*; D002277:Carcinoma / Q000098:blood supply / Q000188:drug therapy* / Q000503:physiopathology; D004354:Drug Screening Assays, Antitumor; D006338:Heart Neoplasms / Q000098:blood supply / Q000188:drug therapy; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000503:physiopathology; D008207:Lymphatic Metastasis; D008297:Male; D009368:Neoplasm Transplantation; D009928:Organ Specificity; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D012517:Sarcoma, Yoshida / Q000098:blood supply / Q000188:drug therapy* / Q000503:physiopathology; D012694:Serine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D012884:Skin Window Technique; D013274:Stomach Neoplasms / Q000098:blood supply / Q000188:drug therapy; D014407:Tumor Cells, Cultured / Q000637:transplantation; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D011355:Prodrugs; D014662:Vasoconstrictor Agents; D012694:Serine; C400245:AC 7700